Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI

Mild Cognitive Impairment (MCI) Clinical Trial

Official title: Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in a Cohort of Patients With Mild Cognitive Impairment

Status Active, not recruiting

Clinical Trial Summary

Mild Cognitive Impairment (MCI) is the moderate impairment of a mental abilities to perform intellectual activities eg memory, calculation, communication... MCI is a disorder that can occur earlier than dementia such as Alzheimer's disease. It is believed that there are several factors involved such as inflammation and oxidative stress which is the production of reactive oxygen species that damage cells.

This clinical study tries to evaluate that a treatment already approved by the AEMPS, EGb 761® (Tebofortan), could reduce the levels of markers of inflammation and oxidation in the blood.

Clinical Trial Description

This treatment is based on a plant called Gingko Biloba. In the study, half of the participants would be administered EGb 761® during 24 months and the other half would not receive this treatment during 12 months and will received EGb 761® for the next 12 months. ;

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Inflammation
• Mild Cognitive Impairment (MCI)

• NCT number: NCT05594355
• Study type: Interventional
• Source: Fundació ACE Institut Català de Neurociències Aplicades
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: April 16, 2021
• Completion date: December 2023